{"id":463182,"date":"2023-11-06T09:39:58","date_gmt":"2023-11-06T08:39:58","guid":{"rendered":"https:\/\/innovationorigins.com\/?p=463182"},"modified":"2023-11-06T09:39:58","modified_gmt":"2023-11-06T08:39:58","slug":"e4-5-million-for-heartbeat-bio-innovating-heart-disease-drug-discovery-with-animal-free-testing","status":"publish","type":"post","link":"https:\/\/ioplus.nl\/archive\/en\/e4-5-million-for-heartbeat-bio-innovating-heart-disease-drug-discovery-with-animal-free-testing\/","title":{"rendered":"\u20ac4.5 million for HeartBeat.bio: Innovating heart disease drug discovery with animal-free testing"},"content":{"rendered":"\n<p><br>Vienna-based HeartBeat.bio, a biotech company working on a scalable platform for heart disease drug discovery, <a href=\"https:\/\/heartbeat.bio\/2023\/11\/02\/heartbeat-bio-raises-e-4-5-million-in-pre-series-a-financingto-drive-development-of-organoid-screening-platform-for-cardiac-drug-discovery\/\">raises<\/a> \u20ac4.5 million. The funding allows for the development of a high-capacity Cardioid Drug Discovery Platform for finding drugs to treat several heart diseases.<\/p>\n\n\n\n<div class=\"io-block io-block__summary\"><ul><li>HeartBeat.bio&#8217;s funding enables high-capacity Cardioid Drug Discovery Platform for heart disease drug development.<\/li><li>The company focuses on animal-free testing with AI.<\/li><\/ul><\/div>\n\n\n\n<p>While cardiovascular diseases are the leading cause of death\u00a0<a href=\"https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death\">worldwide<\/a>, the development of effective therapeutic options is still limited due to high failure rate in clinical drug development and the lack of representative models that can adequately predict the physiology of the human heart.\u00a0HeartBeat.bio\u2019s Cardioid Drug Discovery Platform facilitates the transition from traditional pre-clinical development to an animal-free, human-centric drug discovery approach. <\/p>\n\n\n<div class=\"vlp-link-container vlp-layout-basic wp-block-visual-link-preview-link\"><a href=\"https:\/\/ioplus.nl\/archive\/en\/unprecedented-breakthrough-human-embryo-model-grown-from-stem-cells\/\" class=\"vlp-link\" title=\"Unprecedented breakthrough: human embryo model grown from stem cells\"><\/a><div class=\"vlp-layout-zone-side\"><div class=\"vlp-block-2 vlp-link-image\"><\/div><\/div><div class=\"vlp-layout-zone-main\"><div class=\"vlp-block-0 vlp-link-title\">Unprecedented breakthrough: human embryo model grown from stem cells<\/div><div class=\"vlp-block-1 vlp-link-summary\">Scientists from Israel&#8217;s Weizmann Institute of Science have made an unprecedented breakthrough in embryonic studies, successfully growing a complete human embryo model from stem cells. &hellip; <a href=\"\">Continued<\/a><\/div><\/div><\/div>\n\n\n<p>HeartBeat.bio is building the worldwide first high-throughput human organoid cultivation, screening and AI-supported data analysis solution for developing first-in-class drugs to treat heart failure; faster, less expensively and with a higher probability of success in clinical trials. The so-called Cardioid Drug Discovery Platform relies on self-assembling, highly reproducible cardiac organoids which recapitulate the human physiology and enable modeling of heart diseases in a way not achieved with other\u00a0<em>in-vitro<\/em>\u00a0systems. <\/p>\n\n\n\n<p>Currently, HeartBeat.bio is focused on\u00a0drug-induced\u00a0and\u00a0different sub-types of genetic cardiomyopathies, followed by programs in\u00a0diabetic cardiomyopathy, myocardial infarction, and cardiac remodeling. HeartBeat.bio was founded in 2021 based on technology from the Institute of Molecular Biotechnology (IMBA) and is located at the Vienna BioCenter in Austria.\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Vienna-based HeartBeat.bio, a biotech company working on a scalable platform for heart disease drug discovery, raises \u20ac4.5 million. The funding allows for the development of a high-capacity Cardioid Drug Discovery Platform for finding drugs to treat several heart diseases. While cardiovascular diseases are the leading cause of death\u00a0worldwide, the development of effective therapeutic options is [&hellip;]<\/p>\n","protected":false},"author":2589,"featured_media":494521,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[34665],"tags":[82016,82018],"location":[28214],"article_type":[36684],"serie":[],"archives":[],"internal_archives":[],"reboot-archive":[],"class_list":["post-463182","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-heartbeat-bio","tag-organoid","location-austria","article_type-news"],"blocksy_meta":[],"acf":{"subtitle":"Vienna-based HeartBeat.bio, a biotech company working on a scalable platform for heart disease drug discovery, raises \u20ac4.5 million. ","text_display_homepage":false},"author_meta":{"display_name":"Team IO","author_link":"https:\/\/ioplus.nl\/archive\/author\/erikdevries\/"},"featured_img":"https:\/\/ioplus.nl\/archive\/wp-content\/uploads\/2023\/09\/JH_2.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/ioplus.nl\/archive\/en\/category\/health\/\" class=\"advgb-post-tax-term\">Health<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Health<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/ioplus.nl\/archive\/en\/category\/health\/\" class=\"advgb-post-tax-term\">HeartBeat.bio<\/a>","<a href=\"https:\/\/ioplus.nl\/archive\/en\/category\/health\/\" class=\"advgb-post-tax-term\">organoid<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">HeartBeat.bio<\/span>","<span class=\"advgb-post-tax-term\">organoid<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on November 6, 2023","modified":"Updated on November 6, 2023"},"absolute_dates_time":{"created":"Posted on November 6, 2023 9:39 am","modified":"Updated on November 6, 2023 9:39 am"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/posts\/463182","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/users\/2589"}],"replies":[{"embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/comments?post=463182"}],"version-history":[{"count":0,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/posts\/463182\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/media\/494521"}],"wp:attachment":[{"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/media?parent=463182"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/categories?post=463182"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/tags?post=463182"},{"taxonomy":"location","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/location?post=463182"},{"taxonomy":"article_type","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/article_type?post=463182"},{"taxonomy":"serie","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/serie?post=463182"},{"taxonomy":"archives","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/archives?post=463182"},{"taxonomy":"internal_archives","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/internal_archives?post=463182"},{"taxonomy":"reboot-archive","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/reboot-archive?post=463182"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}